Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$2.01 USD
-0.03 (-1.47%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.99 -0.02 (-1.00%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Acurx Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 12 | 13 | 5 | 6 |
Income After Depreciation & Amortization | -15 | -12 | -13 | -5 | -6 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -15 | -12 | -13 | -5 | -6 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -15 | -12 | -13 | -5 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -15 | -12 | -13 | -5 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -12 | -13 | -5 | -6 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -15 | -12 | -13 | -5 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.67 | 10.82 | 8.54 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.15 | -1.12 | -1.49 | NA | NA |
Diluted Net EPS (GAAP) | -1.15 | -1.12 | -1.49 | -0.74 | NA |
Fiscal Year end for Acurx Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 4.13 | 4.38 | 5.11 | 3.12 | 3.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.13 | -4.38 | -5.11 | -3.12 | -3.45 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -4.12 | -4.38 | -5.11 | -3.11 | -3.45 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.12 | -4.38 | -5.11 | -3.11 | -3.45 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.12 | -4.38 | -5.11 | -3.11 | -3.45 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 15.83 | 15.47 | 13.46 | 13.01 | 12.19 |
Diluted EPS Before Non-Recurring Items | -0.26 | -0.28 | -0.38 | -0.24 | -0.28 |
Diluted Net EPS (GAAP) | -0.26 | -0.28 | -0.38 | -0.24 | -0.28 |